A network meta-analysis of direct factor Xa inhibitors for the treatment of cancer-associated venous thromboembolism

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Federal de São Carlos (UFSCar)-
Autor(es): dc.contributorUniv Colorado-
Autor(es): dc.contributorHosp Clin Porto Alegre-
Autor(es): dc.contributorUniversidade Federal de Minas Gerais (UFMG)-
Autor(es): dc.contributorPontificia Univ Catolica Rio Grande do Sul-
Autor(es): dc.contributorGlobal Res & Innovat Network GRINN-
Autor(es): dc.contributorUniversidade Estadual Paulista (Unesp)-
Autor(es): dc.creatorBrandao, Gustavo Mucoucah Sampaio-
Autor(es): dc.creatorMalgor, Rafael D.-
Autor(es): dc.creatorVieceli, Tarsila-
Autor(es): dc.creatorCandido, Raissa Carolina Fonseca-
Autor(es): dc.creatorInacio, Jose Francisco Secorun-
Autor(es): dc.creatorRodrigues, Clarissa Garcia-
Autor(es): dc.creatorMalgor, Emily A.-
Autor(es): dc.creatorSobreira, Marcone Lima [UNESP]-
Data de aceite: dc.date.accessioned2022-02-22T00:59:07Z-
Data de disponibilização: dc.date.available2022-02-22T00:59:07Z-
Data de envio: dc.date.issued2021-06-25-
Data de envio: dc.date.issued2021-06-25-
Data de envio: dc.date.issued2021-04-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1177/17085381211002726-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/210188-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/210188-
Descrição: dc.descriptionIntroduction Treatment of cancer-associated venous thromboembolism (CAVTE) remains challenging. The aim of this study was to assess the outcomes of direct acting oral anticoagulants (DOAs) for the treatment of CAVTE. Materials and methods A network meta-analysis of randomized clinical trials comparing DOAs (Apixaban, Rivaroxaban, and Edoxaban) versus Dalteparin for the treatment of CAVTE was performed. Outcomes of interest included, VTE recurrence, all-cause mortality, event-free survival, major bleeding, and clinically relevant non-major bleeding (CRNMB). Analysis was based on a random effects model and Bayesian Markov-chain Monte Carlo method was used for indirect comparisons. Results Four RCTs involving 2894 patients were included. Overall certainty of evidence was moderate regarding all outcomes. DOAs exhibited lower risk of VTE (RR 0.62; 95% CI 0.44, 0.87; P = 0.007), similar risk of major bleeding (RR 1.33; 95% CI 0.84, 2.11; P = 0.23), and higher risk of CRNMB (RR 1.66, 95% CI 1.08, 2.56; P = 0.02), compared with Dalteparin. Risk of all-cause mortality and event-free survival were similar between groups with RR 0.99 (95% CI 0.84, 1.16) and RR 1.03 (95% CI 0.94, 1.13), respectively. Apixaban ranked first for recurrent VTE (42.4%) and major bleeding (62.3%) and Dalteparin ranked first for CRNMB (54.7%). Rivaroxaban ranked best considering all-cause mortality (58.7%); Apixaban ranked best for event-free survival (83.6%). Conclusions DOAs presented a reduced risk of recurrent VTE with similar risk of major bleeding compared to Dalteparin. However, a higher risk of CRNMB is expected when this cohort of patients are treated with DOAs instead of Dalteparin.-
Descrição: dc.descriptionUniv Fed Sao Carlos, Dept Med, Sao Carlos Campus, Sao Carlos, Brazil-
Descrição: dc.descriptionUniv Colorado, Anschutz Med Ctr, Aurora, CO USA-
Descrição: dc.descriptionHosp Clin Porto Alegre, Porto Alegre, RS, Brazil-
Descrição: dc.descriptionUniv Fed Minas Gerais, Fac Pharm, Belo Horizonte Campus, Belo Horizonte, MG, Brazil-
Descrição: dc.descriptionPontificia Univ Catolica Rio Grande do Sul, Porto Alegre, RS, Brazil-
Descrição: dc.descriptionGlobal Res & Innovat Network GRINN, Joinville, SC, Brazil-
Descrição: dc.descriptionSao Paulo State Univ, Med Sch, Div Vasc & Endovasc Surg, Botucatu Campus, Botucatu, SP, Brazil-
Descrição: dc.descriptionSao Paulo State Univ, Med Sch, Div Vasc & Endovasc Surg, Botucatu Campus, Botucatu, SP, Brazil-
Formato: dc.format16-
Idioma: dc.languageen-
Publicador: dc.publisherSage Publications Ltd-
Relação: dc.relationVascular-
???dc.source???: dc.sourceWeb of Science-
Palavras-chave: dc.subjectDirect oral anticoagulants-
Palavras-chave: dc.subjectvenous thromboembolism-
Palavras-chave: dc.subjectcancer-
Título: dc.titleA network meta-analysis of direct factor Xa inhibitors for the treatment of cancer-associated venous thromboembolism-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.